U.S. markets close in 3 hours 48 minutes
  • S&P 500

    3,885.49
    -16.33 (-0.42%)
     
  • Dow 30

    31,476.20
    -59.31 (-0.19%)
     
  • Nasdaq

    13,452.29
    -136.54 (-1.00%)
     
  • Russell 2000

    2,244.87
    -30.45 (-1.34%)
     
  • Crude Oil

    60.75
    +0.11 (+0.18%)
     
  • Gold

    1,730.20
    +7.20 (+0.42%)
     
  • Silver

    26.69
    +0.02 (+0.06%)
     
  • EUR/USD

    1.2082
    +0.0022 (+0.18%)
     
  • 10-Yr Bond

    1.4090
    -0.0370 (-2.56%)
     
  • GBP/USD

    1.3963
    +0.0043 (+0.31%)
     
  • USD/JPY

    106.6970
    -0.0330 (-0.03%)
     
  • BTC-USD

    47,771.70
    -1,347.72 (-2.74%)
     
  • CMC Crypto 200

    957.89
    -28.76 (-2.91%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Recap: Alcon Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Alcon (NYSE:ALC) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 8.89% over the past year to $0.41, which were in line with the estimate of $0.41.

Revenue of $1,925,000,000 higher by 2.34% year over year, which beat the estimate of $1,890,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

View more earnings on ALC

Revenue guidance hasn't been issued by the company for now.

Technicals

52-week high: $76.26

Company's 52-week low was at $39.37

Price action over last quarter: Up 10.91%

Company Profile

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.